Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentNEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medical treatments:Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentArticle content“Accelerating scientific progress depends on both rigor and urgency, and we thank the Administration and welcome this Executive Order as an important recognition of the persistent unmet treatment needs in serious mental illness,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “We applaud the Administration’s recognition that psychedelic medicines may represent meaningful new treatment options for patients. We are advancing a comprehensive clinical development program for DT120 (lysergide tartrate) for millions of patients living with conditions including generalized anxiety disorder (GAD) and major depressive disorder (MDD). A science-driven framework that supports rigorous evaluation, responsible access, and faster translation of innovation into care is essential, and the FDA’s evidence-based approval process provides the most effective path to safely delivering these therapies to patients.”Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentThe Executive Order directs coordinated federal action to prioritize mental health therapies, streamline regulatory pathways, and expand cross-agency collaboration, consistent with the Administration’s policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic medicines that could help save lives and address the serious mental health crisis in America. Definium Therapeutics remains committed to advancing rigorous clinical science to develop safe and effective psychedelic treatments and looks forward to continued collaboration with federal agencies, clinicians, researchers, and patient communities to advance evidence-based solutions for mental health disorders.Article contentAbout DT120 Orally Disintegrating Tablet (ODT)Article contentDT120 ODT (lysergide tartrate) is an ergoline derivative belonging to the group of classic serotonergic psychedelics which acts as a partial agonist at specific serotonin receptors (human serotonin-2A (5-HT2A) receptors). DT120 ODT is Definium’s proprietary and pharmaceutically optimized formulation of LSD. DT120 ODT is an advanced formulation incorporating Catalent’s Zydis® ODT fast-dissolve technology, designed to deliver several unique advantages, including faster absorption and onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and a lower incidence of gastrointestinal side effects. Definium is developing DT120 ODT, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and is exploring its potential applications in other serious brain health disorders.Article contentArticle contentAbout Definium TherapeuticsArticle contentThe mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.Article contentFor more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.Article contentArticle contentArticle contentView source version on businesswire.com: Article content https://www.businesswire.com/news/home/20260418158429/en/Article contentArticle contentContactsArticle contentInvestors: Article contentArticle contentGitanjali JainArticle contentArticle contentVP, Head of Investor RelationsArticle contentArticle contentir@definiumtx.comArticle contentMedia: Article contentArticle contentmedia@definiumtx.comArticle contentTrending Bank of Canada's Macklem says he has spoken to Fed chair about risks from Anthropic's Mythos AI model Banking IMF sees Canada's fiscal position as strongest in G7 Economy Brace for gas price 'shock' in inflation numbers out Monday, say economists Economy 'The impacts are massive': U.S. tariff change pushes Canadian manufacturers to the brink Economy Carney invites global CEOs to 'first-ever' Canada Investment Summit this September Economy Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Bank of Canada's Macklem says he has spoken to Fed chair about risks from Anthropic's Mythos AI model Banking IMF sees Canada's fiscal position as strongest in G7 Economy Brace for gas price 'shock' in inflation numbers out Monday, say economists Economy 'The impacts are massive': U.S. tariff change pushes Canadian manufacturers to the brink Economy Carney invites global CEOs to 'first-ever' Canada Investment Summit this September Economy